Moshe Finel
Papers
1
Total Citations
22
H-Index
1
About
Moshe Finel is a leading expert in drug metabolism, with a primary focus on UDP-glucuronosyltransferases (UGTs), a key family of enzymes responsible for detoxifying drugs and endogenous compounds. His major contributions center on developing innovative high-throughput screening (HTS) assays to evaluate UGT-mediated glucuronidation, a critical process for predicting drug toxicity and drug-drug interactions. His seminal 2007 work on an HTS assay for UGT1A1 profiling, which has garnered 22 citations, exemplifies his commitment to advancing preclinical drug development by enabling faster, more cost-effective identification of problematic drug candidates. Finel’s research has significantly improved the understanding of how compounds are metabolized and cleared from the body, directly impacting the design of safer pharmaceuticals. His achievements include pioneering methods that streamline toxicity screening, reducing late-stage drug failures and enhancing patient safety. Through his work, Finel has become a pivotal figure in pharmacogenomics and drug metabolism, providing essential tools for researchers and pharmaceutical scientists aiming to optimize therapeutic efficacy and minimize adverse effects.
Research Focus
Key Achievements
Top Papers
- 1